Pharmacokinetics of ciprofloxacine in pediatric patients, a pilot study – SAFE PEDRUG.

Ghent University Hospital0 个研究点目标入组 20 人开始时间: 2015年1月12日最近更新: 2018年9月3日

试验速览

暂无简介。

•fUTI group:
•-Patients aged 3 months-16 years admitted to the pediatric department of University Hospital Brussels (UZB)
•- rectal body temperature of 38.5 °C.
•-Significant leukocyturia or a positive urine nitrite test in a sterile urine sample
•-ICF signed by both parents or official caregivers
•Prophylaxis group:
•-Patients at any age of the pediatric clinics of both University Hospital Ghent (UZG) and UZB who use cipro (at discretion of their treating physician) for preventing urinary tract infections
•-ICF signed by both parents or official caregivers
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 20
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Impaired renal function as defined by 2x serum creatinin level for age and sex
•Myasthenia gravis
•Long QT-syndrome
•Glucose 6 phosphatase deficiency (G6PD)
•Allergy to one of the substances of cipro
•Concomitant use of corticosteroids
•For the prophylaxis group: co medication of antacidic drugs, ferrofumarate, calcium, magnesium or Zinc supplements

发起方